Skip to main content

A Facility Inspection Checklist

BayBiotech.NET

Whether you are a Quality Assurance/ Compliance personnel planning to make a visit for a facility inspection, this checklist will help you prepare an inspection report based on the information that might be required to collect about the facility during the inspection. This checklist may help you evolve different forms for the inspection in order to accumulate complete information about the facility:

1.General information
(a) name of establishment inspected
(b) date of inspection
(c) name(s) of the inspector(s)
(d) date of last inspection.

2.Type of inspection
Comprehensive, concise, follow-up, special, investigative, announced, and unannounced.

3.Licensing
(a) licensing of premises
(b) person with supervisory role in establishments
(c) adherence to licensing provisions.

4. Activities undertaken on premises
manufacturing, wholesale, importation, export, retail, hospital, pharmacy, clinic, nursing and maternity homes.

5. Adequacy and suitability of premises
(a) premises clean, tidy and in good state of repair
(b) premises secure
(c) floor durable and easily cleaned
(d) premises constructed to prevent infestation by vermin and pests
(e) changing rooms and toilet available
(f) adequacy of lighting and ventilation
(g) appropriate layout of premises.

6. Warehouse/store
(a) adequacy and suitability of warehouse/store
(b) warehouse/store clean and uncluttered
(c) warehouse/store inaccessible to unauthorized persons
(d) temperature and humidity control
(e) enforcement of stock rotation
(f) adequacy of shelving
(g) existence of areas for returned, recalled, quarantined or expired products
(h) warehouse/store free from vermin and insects.

7. Special storage
(a) availability of cold room storage or refrigerator for vaccines and
biological products
(b) suitability of the cold storage facilities
(c) standard written procedure prepared by an appropriate national
regulatory agency for the maintenance of cold chain
(d) special storage area for controlled drugs and other prescription drugs
(e) suitable and secure storage facility for controlled drugs and poisons.

8. Record-keeping
(a) name and address of supplier of each product with date
(b) name and address of purchaser of each product with date
(c) supplier or purchaser license
(d) retention of order forms, copy of delivery notes, stores receipt, and issue vouchers, and book of records (controlled drugs book/prescription drugs book) on the premises as provided for in the drug laws
(e) accuracy of records kept.

9. Conditions for sale and supply
(a) sale and supply of product under the control of an authorized personnel
(b) sale and supply of product from registered/licensed premises
(c) sale of prescription (drugs) on the basis of valid prescription

10. Diversion of controlled products
Diversion of controlled products prevented by examining the records and by physical examination of stock.

11. Returned and expired products
Procedures in place for handling returned and time-expired products.

12. Product recalls
Procedures in place for recall of products and handling recalled products.

13. Product complaints
Procedures in place for dealing with complaints about products.

14. Promotional activities
Assess promotional materials for compliance with laws.

15. Personnel
(a) person responsible for supervising sale in a wholesale/retail pharmacy is a registered/licensed pharmacist
(b) name of the personnel
(c) personnel wears clean protective clothing.

16. Labeling of products and package inserts
Check adequacy of labeling of products and information on package inserts.

17. Physical examination and sampling of products
Conduct physical examination of products in stock and take samples for quality assessment.

18. Reference books
Check existence of reference books on premises, where they are required.

19. Guidance on sampling
(a) Check that the sample is properly labeled with the following:
(I) name of sampled pharmaceutical preparation
(II) batch number
(III) date and source of sample; the original manufacturer's label may be helpful.

(b) Check that the records contain the following:
(I) number of samples
(II) types of packaging and storage conditions
(III) circumstances of sampling that may include suspected quality defects.

(c) Place seals on containers of the samples.
(d) Hand over one-third of the samples to the representative of the inspected establishment.
(e) Confirm in writing that samples were taken from the premises and have the confirmation countersigned by an appropriate official of the inspected establishment.

Overall it is the management's objective to manufacture the product as per the specifications and guidelines.
Records Maintenance for Equipments in Use

Records of major equipment use, cleaning, sanitization, maintenance etc should show the date, time (if appropriate), product, and batch number of each batch processed in the equipment, and the person who performed the cleaning and maintenance.

Comments

  1. software test consultingNovember 27, 2010 at 2:19 AM

    thank you for sharing with us your knowledge. it's the first time i heard about this checklist, i will use it to improve the quality assurance.

    ReplyDelete

Post a Comment

Popular posts from this blog

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...
Post a Comment
Read more

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...
Post a Comment
Read more

Risk Based Clinical Monitoring

BayBiotech.NET FDA's recommendation of Risk Based Monitoring of Clinical Trials , as published in their Draft Guidance in August 2011. For the first time, FDA provided guidance on monitoring of clinical investigations in 1988 which was recently withdrawn, stated that the “most effective way” to monitor an investigation was to “maintain personal contact between the monitor and the investigator throughout the clinical investigation.” At the time the guidance was issued, sponsors had only limited ways to effect meaningful communication with investigators other than through on-site visits.   This guidance recommends an assessment by the sponsor for the need of 100% on-site monitoring. Such an assessment may be based on the complexity of the study protocol and not be generally applicable to all trial types. It explains the importance of remote monitoring facilitated by the use of electronic data capture system (EDC) and also emphasizes the need of the identifying crit...
1 comment
Read more